FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
This article was originally published in The Tan Sheet
Executive Summary
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.
You may also be interested in...
Issa Scolds FDA On Failure To Inspect McNeil Plant
A key House committee chairman questions why FDA has not inspected McNeil Consumer Healthcare's Puerto Rico plant despite a requirement that the Johnson & Johnson business pay the agency's costs.
J&J Plans To Upgrade Recalled OTCs for Relaunch
Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.
Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012
Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.